Table 2.
Parameters* | Follow-up | ||||
---|---|---|---|---|---|
Pre | 1 month | 3 months | 6 months | p^ | |
BCVA | 0.98 ± 0.21 | 0.65 ± 0.31 | 0.51 ± 0.29 | 0.47 ± 0.31 | <0.0001 |
RS | 11.46 ± 4.91 | 12.23 ± 4.33 | 12.80 ± 4.34 | 13.29 ± 4.40 | 0.003 |
CRS | 8.40 ± 4.76 | 9.38 ± 5.01 | 10.14 ± 4.69 | 11.24 ± 4.89 | 0.002 |
MD | −7.69 ± 4.64 | −7.01 ± 3.97 | −6.31 ± 4.07 | −5.99 ± 4.28 | 0.03 |
BCEA 68.2% | 5.89 ± 6.93 | 4.56 ± 5.23 | 4.12 ± 5.66 | 4.13 ± 5.78 | 0.18 |
BCEA 95.4% | 14.30 ± 16.83 | 9.75 ± 8.51 | 9.39 ± 9.33 | 8.39 ± 8.17 | 0.15 |
BCEA 99.6% | 21.41 ± 24.45 | 17.10 ± 12.12 | 15.44 ± 12.16 | 14.85 ± 10.99 | 0.05 |
*Mean and Standard Deviation (M ± SD) for continuous variables. BCVA, Best Corrected Visual Acuity; BCEA, Bivariate Contour Ellipse Area; RS, Retinal Sensitivity; MD, Mean Deviation; CRS, Central Retinal Sensitivity. ^Friedman’s test.